Christina (Tina) P./LinkedIn
Sep 14, 2026, 04:43
Christina (Tina) P.: Retinopathy Risk With Long-Term HCQ Treatment Detailed in Meta-Analysis
Christina (Tina) P., CEO and Co-Founder of APS Foundation of America, shared on LinkedIn:
“Retinopathy Risk With Long-Term HCQ Treatment Detailed in Meta-Analysis
Eye damage remains uncommon after 15 years, but certain factors increase the risk by John Gever, Contributing Writer, MedPage Today.
A recent meta-analysis details that the risk of retinopathy from long-term hydroxychloroquine (HCQ) treatment remains low initially but increases significantly after decades of continuous use.
Clinical guidelines recommend baseline eye exams and annual ophthalmologic screenings after five years of use to prevent permanent vision loss.
More posts featuring Christina (Tina) P. on Hemostasis Today.
-
Sep 14, 2026, 15:22Meral Kayikcioglu: Why Do Women and Men Differ in LDL-C Management?
-
Sep 14, 2026, 15:22James Crowley: The Complex Role of CRP in Cardiovascular Risk and Atherosclerosis
-
Sep 14, 2026, 15:16Factor XIII Deficiency An Often-Missed Bleeding Disorder
-
Sep 14, 2026, 15:07Raffaele Piccolo: Heparin Against Jellyfish Venom?
-
Sep 14, 2026, 15:06Contemporary Research in Thrombosis and Hemostasis – Seminars in Thrombosis and Hemostasis
-
Sep 14, 2026, 15:00Obi Light Ogbonnia: Improving Outcomes for People Living with Sickle Cell Disease in Nigeria
-
Sep 14, 2026, 14:57Closing the Global Gap in NCD Prevention and Care – ISTH
-
Sep 14, 2026, 14:54Petter Brodin: A New Axis of Functional Variation in Human Immune Cells
-
Sep 14, 2026, 14:50Michael Meneghini: The Metabolic Picture Behind Cardiovascular Risk